Have there been improvements in Alzheimer’s disease drug discovery over the past 5 years?

Peptides Acting as Cognitive Enhancers

(2018) Diego Asua et al.   NEUROSCIENCE

Antipsychotic treatment effects on cardiovascular, cancer, infection, and intentional self-harm as cause of death in patients with Alzheimer's dementia

(2017) R.-E. Nielsen et al.   EUROPEAN PSYCHIATRY

Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer’s disease

(2017) Chris G. Parsons et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015)

(2017) Stanton F. McHardy et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Use of psychotropic medications in relation to neuropsychiatric symptoms, cognition and functional performance in Alzheimer's disease over a three-year period: Kuopio ALSOVA study

(2017) Soili Törmälehto et al.   INTERNATIONAL PSYCHOGERIATRICS

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

(2017) Petr Novak et al.   LANCET NEUROLOGY

Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

(2017) Valery L Feigin et al.   LANCET NEUROLOGY

APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice

(2017) Joanna E Pankiewicz et al.   Molecular Neurodegeneration

Update on Phytochemistry and Pharmacology of Naturally Occurring Resveratrol Oligomers

(2017) Jie Shen et al.   MOLECULES

BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer’s Disease Pathology

(2017) Gerald Koelsch   MOLECULES

Tau-based therapies in neurodegeneration: opportunities and challenges

(2017) Chuanzhou Li et al.   NATURE REVIEWS DRUG DISCOVERY

Stem cell models of Alzheimer’s disease: progress and challenges

(2017) Charles Arber et al.   Alzheimers Research & Therapy

Semagacestat Is a Pseudo-Inhibitor of γ-Secretase

(2017) Shinji Tagami et al.   Cell Reports

“Tau immunotherapy: Hopes and hindrances”

(2017) Koorosh Shahpasand et al.   Human Vaccines & Immunotherapeutics

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

(2016) Eric R. Siemers et al.   Alzheimers & Dementia

Clinical Trials in a Dish: The Potential of Pluripotent Stem Cells to Develop Therapies for Neurodegenerative Diseases

(2016) Kelly M. Haston et al.   Annual Review of Pharmacology and Toxicology

The Prevalence and Incidence of Dementia Due to Alzheimer’s Disease: a Systematic Review and Meta-Analysis

(2016) Kirsten M. Fiest et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Novel Therapeutic Strategies for Dementia

(2016) Ramón Cacabelos et al.   CNS & Neurological Disorders-Drug Targets

Apolipoprotein E as a Therapeutic Target in Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence

(2016) Yu Yamazaki et al.   CNS DRUGS

MCI Patients in Europe: Medication and Comorbidities. The DESCRIPA Study

(2016) Magda Tsolaki et al.   Current Alzheimer Research

Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection

(2016) Ramón Cacabelos et al.   CURRENT PHARMACEUTICAL DESIGN

Can cloud-based tools accelerate Alzheimer’s disease drug discovery?

(2016) Ramón Cacabelos et al.   Expert Opinion on Drug Discovery

Treatment Patterns with Antidementia Drugs in the United States: Medicare Cohort Study

(2016) Daniela Koller et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Current and novel therapeutic molecules and targets in Alzheimer's disease

(2016) Ashwini Kumar et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview

(2016) Rosaliana Libro et al.   MOLECULES

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Overview of Alzheimer’s Disease and Some Therapeutic Approaches Targeting Aβby Using Several Synthetic and Herbal Compounds

(2016) Sandeep Kumar Singh et al.   Oxidative Medicine and Cellular Longevity

Pharmacogenetic considerations in the treatment of Alzheimer's disease

(2016) Ramón Cacabelos et al.   PHARMACOGENOMICS

Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease

(2016) Francesco Panza et al.   Biomed Research International

Brain-derived neurotrophic factor and its clinical implications

(2015) Siresha Bathina et al.   Archives of Medical Science

Roles of resveratrol and other grape-derived polyphenols in Alzheimer's disease prevention and treatment

(2015) Giulio Maria Pasinetti et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Gene therapy for neurological disorders

(2015) Chi-Jing Choong et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Building a roadmap for developing combination therapies for Alzheimer’s disease

(2015) Daniel Perry et al.   Expert Review of Neurotherapeutics

Epigenetics of Aging and Alzheimer’s Disease: Implications for Pharmacogenomics and Drug Response

(2015) Ramón Cacabelos et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug–Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors

(2015) Michael A. Brodney et al.   JOURNAL OF MEDICINAL CHEMISTRY

Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and Aβ pathology and modulates Aβ oligomerization

(2015) Edmond Teng et al.   NEUROBIOLOGY OF DISEASE

Tau Immunotherapy

(2015) Einar M. Sigurdsson   Neurodegenerative Diseases

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

(2015) R. Scott Turner et al.   NEUROLOGY

Immunotherapeutic Approaches for Alzheimer’s Disease

(2015) Thomas Wisniewski et al.   NEURON

Intraperitoneal Administration of a Novel TAT-BDNF Peptide Ameliorates Cognitive Impairments via Modulating Multiple Pathways in Two Alzheimer’s Rodent Models

(2015) Yuanyuan Wu et al.   Scientific Reports

Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS–Cognitive and Affective Study

(2015) Carey E. Gleason et al.   PLOS MEDICINE

Building a roadmap for developing combination therapies for Alzheimer’s disease

(2015) Daniel Perry et al.   Expert Review of Neurotherapeutics

Nerve Growth Factor Gene Therapy

(2015) Mark H. Tuszynski et al.   JAMA Neurology

Direct reprogramming of induced neural progenitors: a new promising strategy for AD treatment

(2015) Siqiang Lai et al.   Translational Neurodegeneration

The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer’s disease amyloid-β peptides

(2015) Xiling Lei et al.   Scientific Reports

A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease

(2014) Eric Karran et al.   ANNALS OF NEUROLOGY

Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease

(2014) Carina Wattmo et al.   BMC Neurology

Donepezil and life expectancy in Alzheimer’s disease: A retrospective analysis in the Tajiri Project

(2014) Kenichi Meguro et al.   BMC Neurology

BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease

(2014) Arun K. Ghosh et al.   CHEMICAL SOCIETY REVIEWS

Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer’s Disease

(2014) Natalia Guzior et al.   CURRENT MEDICINAL CHEMISTRY

Epigenomic Networking in Drug Development: From Pathogenic Mechanisms to Pharmacogenomics

(2014) Ramón Cacabelos   DRUG DEVELOPMENT RESEARCH

Epigenetic drug discovery for Alzheimer’s disease

(2014) Ramón Cacabelos et al.   Expert Opinion on Drug Discovery

AlzPlatform: An Alzheimer’s Disease Domain-Specific Chemogenomics Knowledgebase for Polypharmacology and Target Identification Research

(2014) Haibin Liu et al.   Journal of Chemical Information and Modeling

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

(2014) L. S. Schneider et al.   JOURNAL OF INTERNAL MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Gingko biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: Data from the ICTUS study

(2014) Marco Canevelli et al.   PHYTOMEDICINE

Neurotrophic Natural Products: Chemistry and Biology

(2013) Jing Xu et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Development and Mechanism of γ-Secretase Modulators for Alzheimer’s Disease

(2013) Christina J. Crump et al.   BIOCHEMISTRY

RNA silencing of genes involved in Alzheimer's disease enhances mitochondrial function and synaptic activity

(2013) Maria Manczak et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Alzheimer's disease: Review of hormone therapy trials and implications for treatment and prevention after menopause

(2013) Victor W. Henderson   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990–2010: a systematic review and analysis

(2013) Kit Yee Chan et al.   LANCET

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

(2013) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antioxidant gene therapy against neuronal cell death

(2013) Juliana Navarro-Yepes et al.   PHARMACOLOGY & THERAPEUTICS

Trends in the prevalence of antipsychotic drug use among patients with Alzheimer's disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study

(2013) Carlos Martinez et al.   BMJ Open